ALFA Finder| Revenue growth | 13% YoY revenue growth; doubled over last five years. |
|---|---|
| Margins | EBITDA margin improved to 38-39%; structural expansion from US mix. |
| Demand visibility | Strong visibility in US injectables and Latin American private markets. |
| Management confidence | Extremely high, emphasizing 'anti-fragile' model and zero debt. |
Growth
Revenue grew 13% YoY, while PAT surged 20% due to operating leverage and higher-margin US sales.
Outlook
Targeting 17 injectable lines and doubling own-label US revenue to ₹200cr in FY27.
Risks
Substantial dependence on Latin American tenders and high receivables (136 days) pose liquidity risks.
Earnings Call filed with NSE, NSE: CAPLIPOINT. Summary written with AI assistance from the document.
Caplin Point Laboratories Ltd: key numbers
- Share price
- ₹2,557.80
- Market cap
- ₹19,442 Cr
- Revenue (annual)
- ₹2,187 Cr
- Net profit (annual)
- ₹641.2 Cr
- P/E (TTM)
- 29.2×Sector 43.8×
- Promoter holding
- 70.57%+0.00% QoQ
- FII holding
- 5.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Caplin Point Laboratories Ltd
All →Caplin Point Laboratories Board Meeting Date
Caplin Point schedules a 12 November 2026 board meeting for unaudited quarterly and half-year results. The trading window stays closed until 14 November 2026.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories Price Movement Clarification
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Limited shared a weblink for its 35th AGM Notice and Annual Report for FY 2025-26. The communication targets shareholders with unregistered email addresses.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories Limited scheduled its 35th Annual General Meeting for September 25, 2026. Key agenda items include adopting financial statements and declaring a ₹4 final dividend.